benralizumab   Click here for help

GtoPdb Ligand ID: 7674

Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
Approved drug Immunopharmacology Ligand
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: benralizumab

Immunopharmacology Comments
This antibody targets the interleukin 5 receptor alpha subunit (IL5RA; IL-5Rα) [5]. Antibody targeting of IL-5Rα depletes eosinophils in lung tissue and bone marrow, thereby reducing eosinophilic inflammation caused by allergen exposure [1,7].
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Approved drug for severe eosinophilic asthma. 2